Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of solid tumor * Advanced or metastatic disease\* NOTE: \*With the exception of colorectal and lung cancer patients, all patients must receive approval from the insurance carrier that allows for coverage/payment of the study drug bevacizumab * Refractory to standard therapy OR no standard therapy exists * No advanced ovarian cancer or peritoneal carcinomatosis * No metastases from any cancer causing significant ascites * No lung malignancy with any of the following characteristics: * In close proximity to a major vessel * Centrally located * Cavitary * Squamous histology * Hemoptysis \> ½ teaspoon per day PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Platelet count ≥ 100,000/mm\^3 * Absolute neutrophil count ≥ 1,500/mm\^3 * Bilirubin \< 2 mg/dL * AST or ALT \< 3 times upper limit of normal * Creatinine \< 2 mg/dL * Urine protein:creatinine ratio ≤ 1.0 * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Able to tolerate oral therapy * No bleeding diatheses or coagulopathy * No impairment of gastrointestinal (GI) function or GI disease that may affect or alter absorption of imatinib mesylate and/or cyclophosphamide (e.g., malabsorption syndrome, history of total gastrectomy/significant small bowel resection) * No abdominal fistula, GI perforation, or intra-abdominal abscess within the past 6 months * No uncontrolled hypertension (i.e., blood pressure \> 150/100 mm Hg) * No uncontrolled cardiovascular disease, including any of the following: * Coronary artery disease * Uncontrolled cardiac arrhythmia * Symptomatic congestive heart failure (i.e., New York Heart Association class II-IV) * Unstable angina pectoris * Clinically significant peripheral vascular disease * No arterial thromboses within the past year, including any of the following: * Transient ischemic attack * Myocardial infarction * Cerebrovascular event * Unstable angina * Angina requiring medical or surgical intervention * Clinically significant peripheral artery disease * Any other arterial thromboembolic event * No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung * No serious nonhealing wound, ulcer, or bone fracture * No other active second malignancy except nonmelanoma skin cancer or cervical carcinoma in situ unless therapy has been completed and \< 30% risk for relapse exists * No active infection or known HIV infection * No history of allergic reactions (≥ grade 3 or 4) to compounds of similar chemical or biologic composition to cyclophosphamide (i.e., alkylating agents) * No history of noncompliance with medical regimens * No known intolerance or hypersensitivity reaction to bevacizumab, imatinib mesylate, or cyclophosphamide * No other significant medical illness, psychiatric illness, or social situation that, in the opinion of the investigator, would limit compliance with study requirements * No inability to grant reliable informed consent PRIOR CONCURRENT THERAPY: * No major surgical procedure within the past 28 days or anticipated major surgery during study treatment except for placement of a venous access device or surgery for a diagnostic study